112 related articles for article (PubMed ID: 633577)
1. Effect of vidarabine on chronic hepatitis B virus infection.
Pollard RB; Smith JL; Neal A; Gregory PB; Merigan TC; Robinson WS
JAMA; 1978 Apr; 239(16):1648-50. PubMed ID: 633577
[No Abstract] [Full Text] [Related]
2. Relationship between HBV-specific DNA polymerase and HBe antigen/antibody system in chronic HBV infection: factors determining selection of patients and outcome of antiviral therapy.
Craxi A; Weller IV; Bassendine MF; Fowler MJ; Monjardino J; Thomas HC; Sherlock S
Gut; 1983 Feb; 24(2):143-7. PubMed ID: 6852624
[TBL] [Abstract][Full Text] [Related]
3. HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine.
Chadwick RG; Bassendine MF; Crawford EM; Thomas HC; Sherlock S
Br Med J; 1978 Aug; 2(6136):531-3. PubMed ID: 698557
[TBL] [Abstract][Full Text] [Related]
4. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside.
Scullard GH; Andres LL; Greenberg HB; Smith JL; Sawhney VK; Neal EA; Mahal AS; Popper H; Merigan TC; Robinson WS; Gregory PB
Hepatology; 1981; 1(3):228-32. PubMed ID: 6169615
[No Abstract] [Full Text] [Related]
5. [Effects of adenine arabinoside on duck hepatitis B virus infection. Analysis of intrahepatic replicative DNA].
Hirota K; Omata M; Yokosuka O; Imazeki F; Uchiumi K; Ito Y; Okuda K
Nihon Shokakibyo Gakkai Zasshi; 1987 Jan; 84(1):58-64. PubMed ID: 3573385
[No Abstract] [Full Text] [Related]
6. Antiviral treatment of chronic type B hepatitis.
Hoofnagle JH
Ann Intern Med; 1987 Sep; 107(3):414-5. PubMed ID: 2441635
[No Abstract] [Full Text] [Related]
7. [Vidarabine treatment of chronic active hepatitis associated with hepatitis B virus multiplication. A randomized multicenter study].
Ouzan D; Degos F; Marcellin P; Linberg J; Chevallier M; Degott C; Bréchot C; Chossegros P; Weiss AM; Hirtz J
Gastroenterol Clin Biol; 1987; 11(8-9):568-73. PubMed ID: 3308617
[TBL] [Abstract][Full Text] [Related]
8. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study.
Bassendine MF; Chadwick RG; Salmeron J; Shipton U; Thomas HC; Sherlock S
Gastroenterology; 1981 May; 80(5 pt 1):1016-22. PubMed ID: 7009310
[TBL] [Abstract][Full Text] [Related]
9. [Development of acute hepatitis to chronicity].
Sapunar I
Acta Gastroenterol Latinoam; 1986; 16(1):61-3. PubMed ID: 3577621
[No Abstract] [Full Text] [Related]
10. Evaluation of the antiviral effects of adenine arabinoside on chronic HBV infection.
Watanabe S; Saito S; Yoshikawa A; Shibayama T; Kamimura T; Suzuki S; Ischida F
Hepatogastroenterology; 1982 Jun; 29(3):102-5. PubMed ID: 7106692
[TBL] [Abstract][Full Text] [Related]
11. [Serologic markers of hepatitis B virus. Recent progress].
Mora Pérez I; Porres Cubero JC; Carreño García V
Rev Clin Esp; 1984 Apr; 173(1):9-14. PubMed ID: 6330799
[No Abstract] [Full Text] [Related]
12. [Markers of viral replication (HBeAg and DNA polymerase activity) in chronic uremia, HBsAg positive, hemodialysis patients].
Dentico P; Buongiorno R; Angarano G; Monno L; Coppola S; Laddago V; Spinelli A; Pastore G
Boll Soc Ital Biol Sper; 1980 Nov; 56(21):2193-9. PubMed ID: 7213481
[TBL] [Abstract][Full Text] [Related]
13. Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics.
Lampertico P; Malter JS; Gerber MA
Hepatology; 1991 Mar; 13(3):422-6. PubMed ID: 1705531
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological response of HBsAg-positive chronic active hepatitis to adenine arabinoside: lack of correlation with DNA polymerase response.
Liaw YF; Lin DY; Chen TJ; Chu CM; Sheen IS
Infection; 1984; 12(4):248-50. PubMed ID: 6490167
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with ARA-AMP and interferon of chronic active hepatitis B. Interim analysis of an ongoing study.
Trépo C; Rougier P; Bizollon T; Poupon R; Zarski JP; Quinton A; Miguet JP; Causse X; Chossegros P; Chevallier M
J Hepatol; 1991; 13 Suppl 1():S3. PubMed ID: 1720439
[No Abstract] [Full Text] [Related]
16. Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study.
Yokosuka O; Omata M; Imazeki F; Hirota K; Mori J; Uchiumi K; Ito Y; Okuda K
Gastroenterology; 1985 Aug; 89(2):246-51. PubMed ID: 4007415
[TBL] [Abstract][Full Text] [Related]
17. Immunological and anti-viral therapy of chronic hepatitis B virus infection.
Thomas HC; Bassendine MF
Clin Gastroenterol; 1980 Jan; 9(1):85-95. PubMed ID: 6156790
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection.
Weller IV; Tedder RS; Karayiannis P; Thomas HC; Fiddian AP
J Hepatol; 1986; 3 Suppl 2():S119-22. PubMed ID: 3598153
[TBL] [Abstract][Full Text] [Related]
19. A radioimmunoassay for HBcAg in the sera of HBsAg carriers: serum HBcAg, liver HBcAg immunofluorescence as markers of chronic liver disease.
Rizzetto M; Shih JW; Verme G; Gerin JL
Gastroenterology; 1981 Jun; 80(6):1420-7. PubMed ID: 7014350
[No Abstract] [Full Text] [Related]
20. Full and empty Dane particles in chronic hepatitis B virus infection: relation to hepatitis B e antigen and presence of liver damage.
Alberti A; Diana S; Scullard GH; Eddleston WF; Williams R
Gastroenterology; 1978 Nov; 75(5):869-74. PubMed ID: 700329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
